RBC Capital Maintains Sector Perform on Gilead Sciences, Raises Price Target to $74
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Brian Abrahams maintains a Sector Perform rating on Gilead Sciences and raises the price target from $72 to $74.
September 04, 2024 | 1:15 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
RBC Capital has maintained its Sector Perform rating on Gilead Sciences and increased the price target from $72 to $74, indicating a slightly positive outlook.
The increase in price target from $72 to $74 by RBC Capital suggests a slightly positive outlook for Gilead Sciences. Although the rating remains Sector Perform, the raised target indicates potential for modest price appreciation.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100